This paper explores the application of EU Competition Law to the exploitation of human genome editing technology. Holders of key patents in the sector have applied different methods for disseminating the technology, such as different forms of licensing agreement and patent pools. It is found that that the competition rules are ill-suited to assess some of the licensing arrangements applied, which give rise to legal uncertainty. Accordingly, holders of patents on human genome editing technology may be discouraged to apply efficient methods for disseminating the technology. This may delay or obstruct some of the benefits the technology is supposed to deliver to the market, maker actors and consumers.

本文探讨了欧盟竞争法在人类基因组编辑技术开发中的应用。该领域关键专利的持有者采用了不同的方法来传播技术，例如不同形式的许可协议和专利池。研究发现，竞争规则不适合评估某些适用的许可安排，从而导致法律不确定性。因此，人类基因组编辑技术的专利持有者可能不愿意应用有效的方法来传播该技术。这可能会延迟或阻碍该技术本应为市场、制造商和消费者带来的一些好处。